Actinium Pharmaceuticals Appoints Steffen Heeger as CMO Effective June 1, 2026

Actinium Pharmaceuticals, Inc. announced the appointment of Steffen Heeger, MD, MSc, as Chief Medical Officer, effective June 1, 2026. Heeger will spearhead the clinical development of Actinium’s pipeline, bringing extensive experience in oncology drug development and clinical trial leadership to the role.

Dr. Heeger’s background includes serving as Chief Medical Officer at ImCheck Therapeutics and as Vice President, Clinical Development at MacroGenics. He also held leadership positions at Bayer Healthcare and gained academic research experience at the National Institutes of Health (NIH). Actinium anticipates that Dr. Heeger’s expertise will be instrumental in advancing their therapeutic programs.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI